Wang Le, Li Dandan, Yao Fang, Feng Shanshan, Tong Chao, Rao Rongjia, Zhong Meiyan, Wang Xianqiang, Feng Wei, Hu Zhan, Jin Bo, Wang Li, Hu Shengshou, Zhou Bingying
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.
Department of Clinical Laboratory, Peking University First Hospital, Beijing, China.
Nat Commun. 2025 Jan 25;16(1):1012. doi: 10.1038/s41467-024-55589-w.
Lactate produced during ischemia-reperfusion injury is known to promote lactylation of proteins, which play controversial roles. By analyzing the lactylomes and proteomes of mouse myocardium during ischemia-reperfusion injury using mass spectrometry, we show that both Serpina3k protein expression and its lactylation at lysine 351 are increased upon reperfusion. Both Serpina3k and its human homolog, SERPINA3, are abundantly expressed in cardiac fibroblasts, but not in cardiomyocytes. Biochemically, lactylation of Serpina3k enhances protein stability. Using Serpina3k knockout mice and mice overexpressing its lactylation-deficient mutant, we find that Serpina3k protects from cardiac injury in a lysine 351 lactylation-dependent manner. Mechanistically, ischemia-reperfusion-stimulated fibroblasts secrete Serpina3k/SERPINA3, and protect cardiomyocytes from reperfusion-induced apoptosis in a paracrine fashion, partially through the activation of cardioprotective reperfusion injury salvage kinase and survivor activating factor enhancement pathways. Our results demonstrate the pivotal role of protein lactylation in cardiac ischemia-reperfusion injury, which may hold therapeutic value.
已知缺血再灌注损伤期间产生的乳酸会促进蛋白质的乳酰化,而蛋白质的乳酰化作用存在争议。通过使用质谱分析小鼠心肌在缺血再灌注损伤期间的乳酰化蛋白质组和蛋白质组,我们发现再灌注后Serpina3k蛋白表达及其赖氨酸351位点的乳酰化均增加。Serpina3k及其人类同源物SERPINA3在心脏成纤维细胞中大量表达,但在心肌细胞中不表达。从生化角度来看,Serpina3k的乳酰化增强了蛋白质稳定性。使用Serpina3k基因敲除小鼠和过表达其乳酰化缺陷突变体的小鼠,我们发现Serpina3k以赖氨酸351位点乳酰化依赖的方式保护心脏免受损伤。机制上,缺血再灌注刺激的成纤维细胞分泌Serpina3k/SERPINA3,并以旁分泌方式保护心肌细胞免受再灌注诱导的凋亡,部分是通过激活心脏保护的再灌注损伤挽救激酶和存活激活因子增强途径实现的。我们的结果证明了蛋白质乳酰化在心脏缺血再灌注损伤中的关键作用,这可能具有治疗价值。